key: cord-1048343-nxwaw5zv
authors: Tada, Takuya; Zhou, Hao; Dcosta, Belinda M.; Samanovic, Marie I.; Cornelius, Amber; Herati, Ramin S.; Mulligan, Mark J.; Landau, Nathaniel R.
title: High Titer Neutralization of Mu and C.1.2 SARS-CoV-2 Variants by Vaccine-elicited Antibodies of Previously Infected Individuals
date: 2021-12-21
journal: Cell Rep
DOI: 10.1016/j.celrep.2021.110237
sha: bb8b6868455f1f383a251b08008ec304955ad06e
doc_id: 1048343
cord_uid: nxwaw5zv

Recently identified SARS-CoV-2 variants Mu and C.1.2 have spike proteins with mutations that might confer resistance to natural and vaccine-elicited antibodies. Analysis of neutralizing antibody titers in the sera of vaccinated individuals without previous history of infection and from convalescent individuals showed partial resistance of the viruses. In contrast, sera from individuals with a previous history of SARS-CoV-2 infection who were subsequently vaccinated, neutralized variants with titers 4-11-fold higher, providing a rationale for vaccination of infection-experienced individuals. The heavily mutated C.1.2 spike was the most antibody neutralization-resistant spike to date; however, the avidity of C.1.2 spike protein for ACE2 was low. This finding suggests that the virus evolved to escape the humoral response but has a decrease in fitness suggesting that it may cause milder disease or be less transmissible. It may be difficult for the spike protein to evolve to escape neutralizing antibodies while maintaining high affinity for ACE2.

In this study, we measured the infectivity of viruses with the Mu, C.1.2 and Delta+N501S spike 49 proteins and determined their susceptibility to neutralization by convalescent and vaccine-elicited 50 antibodies, both in previously infected and uninfected individuals. Viruses with the variant spikes 51 were partially resistant to neutralization. The C.1.2 variant, which is highly mutated, was the most 52 resistant. Sera from previously infected patients vaccinated with BNT162b2 had high neutralizing 53 titer against all of the variants, providing a strong rationale for the vaccination of previously 54 infected individuals. The resistance of the C.1.2 spike protein to neutralization was largely 55 mediated by the Y449H mutation in the RBD. However, the mutation resulted in a significant 56 decrease in avidity of the spike protein for ACE2. This encouraging finding suggests that while 57 the viral spike protein has managed to mutate to escape neutralizing antibodies, this resulted in 58 a fitness cost that will limit its spread through the human population. Table S1 ) and all participants tested negative for antibodies against the SARS-CoV-2 N protein 100 suggesting no history of SARS-CoV-2 infection (Table S1) 

Overall, the neutralization titers of sera from previously infected donors were 8.5-8.9-fold greater 127 against Mu and C.1.2 variants compared with uninfected individuals. (Table S2) 128 129 Decreased avidity of C.1.2 spike protein for ACE2.

To measure the ACE2 avidity of the variant spikes, we established an ACE2 avidity assay in which 

In this assay, virions with D614G, Beta, Delta, Delta+N501S, C.1.2 (RBD) and Mu spikes bound 145 similarly to ACE2 while C.1.2 avidity was decreased. These findings suggest that the C.1.2 spike 146 protein binds ACE2 with a relatively lower avidity than the other spike protein variants. titer that is 20% that of the convalescent titer will provide 50% protection from SARS-CoV-2 174 infection (Khoury et al., 2021) . In our study, the mean convalescent titer was 334 (Table S1),

predicting that an IC50 of 67 would correspond to 50% protection. The model further predicts that 176 an antibody titer that is 3% that of the mean titer of convalescent sera titer is required to protect 177 against severe disease, corresponding to a titer of 10 in our study and suggesting that vaccination 

The high titer and breadth of the antibody response suggests that it will protect against current 190 variants and is likely to protect against future variants that may arise. 

The viruses used in this study had the modified C.1.2 (-T716I) spike protein to ensure confidence 199 in the results. The cause of the decreased infectivity of spike proteins with the T716I mutation is mutation had no effect on expression of the spike protein in transfected cells, packaging into 204 virions or avidity for ACE2. The mutation also had no effect on antibody neutralization profile 205 ( Figure S4) . While the T716I mutation did not influence the results in our study, its effect should 206 be considered in studies with lentiviral pseudotypes with spike proteins that have the mutation.

In this study, we measured spike protein avidity for ACE2 using a novel assay in which we 209 incubated an ACE2:luciferase fusion protein with spike protein expressing cells and then 210 determined the amount of bound fusion protein by luciferase assay. A comparison of the avidities 211 measured by this method with those the published for the spike:ACE2 interaction correspond closely, validating our method. We measured a Kd of 60 nM for the D614G spike:ACE2 interaction, 

The emergence of the Mu and C.1.2 variants do not appear to raise new public health concerns.

Mu is nearly identical to Delta with the exception of the conservative R346K mutation. As of 224 October, 2021, the variant has been found in Europe and North and South America with a total of 225 3689 cases in Colombia, 5604 cases in North America and 12762 cases worldwide and there is 226 no evidence for increasing prevalence (outbreak.info., 2021a). The C.1.2 variant is currently at 227 low prevalence with a highly restricted geographic distribution. The high titers of antibody against 228 all of the variants in individuals with a history of previous infection is encouraging demonstrates 229 the ability of individuals to mount a broadly neutralizing antibody response that will protect against 230 these variants. Moreover, the breadth of the vaccine response in such individuals suggests that It is interesting that the C.1.2 spike protein has a decreased avidity for ACE2 compared to that of 234 the other variant spikes. Its RBD has the N501Y mutation that confers increased avidity for ACE2 235 (Gu et al., 2020; Starr et al., 2020) 

CHO cells at a density of 2.4 X 10 9 cells (6 X 10 6 cells/ml) were transfected with 400g of 383 sACE2-NLuc expression vector plasmid DNA using ExpiFectamine CHO Reagent 384 (Thermo Fisher Scientific). The following day, ExpiCHOTM Enhancer was added and 385 culture was continued at 32°C for another 5 days after which the culture medium was 386 collected and passed through a 2.5 M pore size filter. The fusion protein was purified by proteins were washed and luciferase activity was measured using Nano-Glo substrate (Nanolight) 394 in an Envision 2103 microplate luminometer (PerkinElmer).

Neutralization assay by soluble ACE2 397 Briefly, pseudotyped virus was incubated with serially diluted recombinant soluble ACE2 protein 398 for 1 hour at room temperature and subsequently added to 1 X 10 4 ACE2.293T cells. After 2 days, 399 the cell medium was removed and 50 l Nano-Glo luciferase substrate (Nanolight) was added.

The luminescence signal was read in an Envision 2103 microplate luminometer. 

SARS-CoV-2 infection induces sustained humoral immune responses in convalescent 488 patients following symptomatic COVID-19

Structural impact on SARS-CoV-2 spike protein by D614G substitution

SARS-CoV-2 spike-protein D614G mutation increases In brief Tada et al. show that infection with SARS-CoV-2 followed by vaccination results in broadly neutralizing antibody. The C.1.2 variant has a highly mutated spike and is the most neutralization-resistant variant